



Translation of Immediate Report Filed by Elron on November 20, 2022 with the Israeli Securities

Authority

Re: Bioventus Reports for the Third Quarter of 2022

Further to Section 3 of part A of Elron Ventures Ltd.'s (the “**Company**”) quarterly report for the third quarter of 2022, regarding the sale of CartiHeal (2009) Ltd (“**Cartiheal**”) to Bioventus LLC (the “**Transaction**”), and further to Section 4 of part A of the Company’s quarterly report for the second quarter of 2022, the content of which is incorporated herein by reference, the Company hereby updates that on November 16, 2022 Bioventus published an announcement according to which Bioventus requires additional time in order to publish its quarterly report for the third quarter of 2022 (the “**Report**”), and also that the Report is expected to be published by November 21, 2022. In its announcement, Bioventus noted that its management is examining whether Bioventus will be able to fulfill all its financial obligations as they come due within one year after the date of the Report (October 1, 2022).

The following is a link to the Bioventus announcement:

<https://www.sec.gov/Archives/edgar/data/1665988/000162828022030160/nt-10q.htm>